This STAT story does an exemplary job of describing, and putting into context, yet another observational study of the possible links between coffee consumption and health, this one concluding that overall, whether decaf or regular, coffee is associated with reduced risk of death from heart disease, diabetes, and neurological disorders such as Parkinson’s Disease, although not cancer. The great strengths of the story include links to notable previous studies that explain the confusing “backstory” of the coffee consumption/health risk debate among researchers and consumers, along with one of the best definitions of the limitations of observational studies this reviewer has read in a news article. The STAT story gets the quantification and qualification issues down, but also goes the extra mile in noting a strong example of how observational studies can fail consumers and professionals (post-menopausal hormone safety), and in entertainingly giving readers a useful take-home message — drink up, but but understand that while the health benefits are “strongly suggestive,” they are “not definitive.” Extra credits goes to STAT for noting the absolute mortality risk reduction this way: “coffee would [keep] 1 person in 1000 from dying” each year — something a competing CNN story on the same study lacked.
Readers and viewers of mass media have been nearly whiplashed by claims and counterclaims related to the benefits and risks of coffee drinking. A few studies over the past several decades have concluded that, at least in large amounts, coffee can be “toxic,” but most of the coverage has focused on the drink’s possible health benefits, but in ways that led to substantial confusion. The new analysis, described in the American Heart Association journal Circulation, has some significant statistical assets not present in previous studies, including a subset analysis of non-smokers’ death risks. Its central finding — that coffee safely confers health benefits (essentially reduced death risks for some major categories of disease) even in relatively high doses among non-smokers — is likely to be reassuring to coffee addicts — and their physicians.
Arguably, most people know how much their java habit costs them every day, and neither this STAT story nor the competing CNN coverage mentioned costs. Like hazelnut cream, some mention of the overall cost of the coffee habit in the U.S. would have added some flavor, but this omission gets a pass.
STAT’s story, like the coverage in CNN, gets the details, strengths and weaknesses of the data right, but STAT’s piece more precisely quantifies the findings and goes to exceptional lengths to clearly describe what an observational study can and cannot do, and did and did not do in this current piece of analysis.
This STAT story explained the slightly increased risk of death in those participants in the current study who drank very high amounts of coffee,
STAT does a fine job of noting the sources of information used in the new analysis, and repeating — in novel ways — the shortcomings and strengths of the findings. This kind of repetition, although frowned upon in journalistic circles because of space constraints, should be used more often where appropriate to remind readers of the context of each health claim in a story. The CNN story covering this research did a creditable job of describing the data, but how refreshing it is to see how smoothly a news article can reinforce take-home messages in a way readers will understand and remember.
The STAT story included not just any “outside” expert comment, but chose a co-author of a seminal 2013 study, whose professional credibility added to the story’s. And unlike the CNN story, it offered details of the ongoing epidemiological studies from which the new data were drawn.
We thought that a comparison of alternatives to coffee was beyond the scope of the story.
Coffee is widely available, and that’s obvious from the story.
The STAT story, like its CNN counterpart, duly noted the novelty of the researchers’ analysis of the non-smoker subset of records analysis, and STAT did so with a bit more easily-accessible language.
The STAT story was well researched, offering links that could form a small “bibliography” of relevant studies and using an outside commentator to put the new findings in perspective.
Systematic, Criteria-Driven
Come on, NY Times; you must do better than this. Important research doesn’t need hype and the “breaking news” BS doesn’t help readers or patients. https://www.healthnewsreview.org/2022/03/nyt-proclaims-breaking-news/
Our editorial team was blessed to have Sharon as a contributor during our best years. As this obit states, she was “kind, patient, wise, thoughtful and generous.” Thank you, Sharon; now rest in peace. https://journalism.wisc.edu/news/in-memoriam-sharon-dunwoody-1947-2022/
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Comments (4)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Laurence Alter
November 24, 2015 at 5:08 amCan we know who or what “STAT” is?
Laurence Alter
Kevin Lomangino
November 24, 2015 at 8:47 amhttp://www.statnews.com/about/
Kevin Lomangino
Managing Editor
Laurence Alter
November 25, 2015 at 12:34 amDear Kevin,
You are managing editor: possibly you could omit the use of abbreviations (or cutesy pharmaceutical colloquialisms no regular layperson knows) and manage the English language and the representation of your organization better.
Laurence Alter
E-mail: questioning@mail.com
Kevin Lomangino
November 27, 2015 at 9:27 pmDear Laurence,
STAT is the name of the news organization that published the story, not an abbreviation or colloquialism. I thought that was readily apparent from the context. One need only click on the hyperlinked “STAT” logo to ascertain this.
Regards,
Kevin Lomangino
Managing Editor
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like